Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
Condition: Lung Cancer Intervention: Other: Non-interventional Sponsor: Bristol-Myers Squibb Active, not recruiting
ConclusionLow PNI predicts poor survival in LC patients.
With a median survival of 6 to 12 months, small cell lung cancer (SCLC) most commonly presents with metastatic or extensive stage (ES) disease . Cisplatin-based doublet chemotherapy is the mainstay of therapy with high rates of initial response. However, a proportion of patients harbor residual intrathoracic disease, precipitating the hypothesis that consolidative thoracic radiotherapy (TRT) can improve outcomes . Several prospective and retrospective studies have demonstrated a survival benefit with the addition of thoracic radiation in ES-SCLC, including the recent phase III CREST trial which reported a 10% 2-year ...
The new approval is accelerated and is therefore conditional upon further proof of efficacy, but the checkpoint inhibitor becomes the first approved option in advanced SCLC in a long time.FDA Approvals
Bristol-Myers Squibb announced that the U.S. FDA has approved Opdivo as a treatment for certain patients with previously treated small cell lung cancer.
In this study, we had integrated systems pharmacology and bioinformatics to explore the major active ingredients against cancer, targets for cancer treatment, and the related mechanisms of action. These targets were scrutinized using web-based Gene SeT Analysis Toolkit (WebGestalt), and 10 KEGG pathways were identified by enrichment analysis. Refined analysis of the KEGG pathways indicated that the anticancer effect of HJD showed a functional correlation with the p53 signaling pathway; moreover, HJD had potential therapeutic effect on prostate cancer (PCa) and small cell lung cancer (SCLC). Afterwards, genetic alterations ...
Long non‑coding RNAs in small cell lung cancer: A potential opening to combat the disease (Review). Oncol Rep. 2018 Aug 07;: Authors: Li TT, He RQ, Ma J, Li ZY, Hu XH, Chen G Abstract Lung cancer is the top cause of cancer‑associated mortality in men and women worldwide. Small cell lung cancer (SCLC) is a subtype that constitutes ~15% of all lung cancer cases. Long non‑coding RNAs (lncRNAs), possessing no or limited protein‑coding ability, have gained extensive attention as a potentially promising avenue by which to investigate the biological regulation of human cancer. lncRNAs can modulate gen...
ConclusionThere is relationship between PET –CT metabolic parameters and NLR in SCLC. Highest correlation was found with NLR and MTV, WBMTV, and WBTLG, and evaluation of NLR together with these parameters predicts survival times and tumor biology more clearly in SCLC.
The prognosis of small cell lung cancer (SCLC) is poor despite its good initial response to chemotherapy. Polo-like kinase 1 (PLK1) is a crucial mitotic regulator that is overexpressed in many tumors, and its overexpression is associated with tumor aggressiveness and a poor prognosis. However, its role in SCLC is still poorly characterized. Based on immunohistochemistry findings, the PLK1 protein is expressed at higher levels in SCLC tumor samples than in normal lung tissue samples. The selective PLK1 inhibitor BI 6727 significantly induced the inhibition of proliferation and apoptosis in a dose-dependent manner in SCLC cell lines.
CONCLUSIONS: Our results suggest that polymorphic CCND1 may increase the risk of lung cancer in smokers from North India, and it may be associated with the overall survival of SCLC patients. PMID: 30086699 [PubMed - in process]
Conclusions Multimodality treatment including surgery was safe and led to considerable survival. R0 resection was the only factor extending survival. It could be achieved in most patients and was associated with a low risk of locoregional relapse. Prospective randomized controlled studies are needed to define best practice in stage IA–IIIB SCLC. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents | Abstract | Full text